Published in Nature on March 02, 2016
Thermoneutral housing exacerbates nonalcoholic fatty liver disease in mice and allows for sex-independent disease modeling. Nat Med (2017) 1.40
Autophagy, Inflammation, and Immunity: A Troika Governing Cancer and Its Treatment. Cell (2016) 1.21
The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer (2016) 0.95
T-cell metabolism governing activation, proliferation and differentiation; a modular view. Immunology (2016) 0.79
Foxp3 drives oxidative phosphorylation and protection from lipotoxicity. JCI Insight (2017) 0.78
Liver macrophages in tissue homeostasis and disease. Nat Rev Immunol (2017) 0.78
Dysregulation of redox pathways in liver fibrosis. Am J Physiol Gastrointest Liver Physiol (2016) 0.76
Gender Differences in Adipocyte Metabolism and Liver Cancer Progression. Front Genet (2016) 0.76
Type I Interferon Responses Drive Intrahepatic T cells to Promote Metabolic Syndrome. Sci Immunol (2017) 0.75
Tumor regulation of the tissue environment in the liver. Pharmacol Ther (2017) 0.75
Getting the Skinny on CD4(+) T Cell Survival in Fatty Livers. Immunity (2016) 0.75
Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. World J Gastroenterol (2016) 0.75
New players in non-alcoholic fatty liver disease induced carcinogenesis: lipid dysregulation impairs liver immune surveillance. Hepatobiliary Surg Nutr (2016) 0.75
Loss of Dnmt3a and Dnmt3b does not affect epidermal homeostasis but promotes squamous transformation through PPAR-γ. Elife (2017) 0.75
Choline Deficiency Causes Colonic Type II Natural Killer T (NKT) Cell Loss and Alleviates Murine Colitis under Type I NKT Cell Deficiency. PLoS One (2017) 0.75
Inflammation, mitochondrial metabolism and nutrition: the multi-faceted progression of non-alcoholic fatty liver disease to hepatocellular carcinoma. Hepatobiliary Surg Nutr (2016) 0.75
Mitochondrial Superoxide Signaling Contributes to Norepinephrine-Mediated T-Lymphocyte Cytokine Profiles. PLoS One (2016) 0.75
Minimum absolute lymphocyte counts during radiation are associated with a worse prognosis in patients with unresectable hepatocellular carcinoma. Therap Adv Gastroenterol (2016) 0.75
Comments on "NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis". Hepatobiliary Surg Nutr (2016) 0.75
Immune surveillance of liver cancer in non-alcoholic fatty liver disease: excess lipids cause CD4 T-cells loss and promote hepatocellular carcinoma development. Hepatobiliary Surg Nutr (2016) 0.75
NAFLD: Loss of CD4(+) T cells in HCC. Nat Rev Gastroenterol Hepatol (2016) 0.75
Gastrointestinal Complications of Obesity. Gastroenterology (2017) 0.75
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol (2012) 16.93
Removal of fatty acids from serum albumin by charcoal treatment. J Biol Chem (1967) 12.40
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature (2012) 10.74
Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell (2010) 8.04
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature (2011) 6.14
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature (2004) 5.61
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology (2008) 4.23
CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell (2010) 3.33
Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature (2015) 2.76
CD4+ FoxP3+ regulatory T cells confer infectious tolerance in a TGF-beta-dependent manner. J Exp Med (2008) 2.72
A high-fat diet and regulatory T cells influence susceptibility to endotoxin-induced liver injury. Hepatology (2007) 2.52
Dendritic cells limit fibroinflammatory injury in nonalcoholic steatohepatitis in mice. Hepatology (2013) 2.42
ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell (2014) 2.31
Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res (2008) 2.21
NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol (2013) 2.20
Obesity, inflammation, and liver cancer. J Hepatol (2011) 2.09
Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut (2011) 2.06
Proteomic and lipidomic signatures of lipid metabolism in NASH-associated hepatocellular carcinoma. Cancer Res (2013) 1.88
Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice. Hepatology (2013) 1.80
Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. J Hepatol (2013) 1.80
Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine. J Clin Invest (2009) 1.75
From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol (2013) 1.75
Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis. Gut (2008) 1.65
Fatty acids as modulators of the cellular production of reactive oxygen species. Free Radic Biol Med (2008) 1.55
Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Lipid Res (2010) 1.53
Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice. Hepatology (2013) 1.48
Interferon-alpha activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes. Gastroenterology (2002) 1.48
A mitochondrial switch promotes tumor metastasis. Cell Rep (2014) 1.48
Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell (2014) 1.45
Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol (2013) 1.38
Gr-1+ CD11b+ myeloid-derived suppressor cells suppress inflammation and promote insulin sensitivity in obesity. J Biol Chem (2011) 1.37
CD4(+) Valpha14 natural killer T cells are essential for acceptance of rat islet xenografts in mice. J Clin Invest (2000) 1.09
Involvement of free radicals and oxidative stress in NAFLD/NASH. Free Radic Res (2013) 1.04
Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches. Gut (2015) 1.02
Hepatocellular carcinoma from an immunologic perspective. Clin Cancer Res (2013) 1.00
Metabolite profiling in plasma and tissues of ob/ob and db/db mice identifies novel markers of obesity and type 2 diabetes. Diabetologia (2015) 0.98
Metabolic reprogramming towards aerobic glycolysis correlates with greater proliferative ability and resistance to metabolic inhibition in CD8 versus CD4 T cells. PLoS One (2014) 0.96
Extracellular flux analysis to monitor glycolytic rates and mitochondrial oxygen consumption. Methods Enzymol (2014) 0.93
Measurement of fatty acid oxidation rates in animal tissues and cell lines. Methods Enzymol (2014) 0.91
P(URI)fying Novel Drivers of NASH and HCC: A Feedforward Loop of IL17A via White Adipose Tissue. Cancer Cell (2016) 0.75
Bcl-xL is an oncogenic driver in colorectal cancer. Cell Death Dis (2016) 0.75